20/20 Biolabs Inc. Announces Stand‑Still Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock
20/20 Biolabs Inc., the Nasdaq‑listed company headquartered in Gaithersburg, Maryland, has entered into a stand‑still agreement with Streeterville Capital, a private equity firm that holds a substantial stake in the company. The agreement, disclosed on 23 July 2026, governs the Series E convertible preferred stock that was issued to Streeterville Capital in 2025.
Key Provisions
| Item | Detail |
|---|---|
| Parties | 20/20 Biolabs Inc. (the “Company”) and Streeterville Capital (“Investor”). |
| Instrument | Series E convertible preferred shares issued on 12 August 2025. |
| Stand‑Still Period | For a period of 12 months, the Investor is prohibited from selling, transferring, or otherwise disposing of any shares it holds. |
| Dividend and Conversion Rights | The shares retain their preferred dividend rate and the right to convert into common shares at the originally stated conversion price, subject to the terms of the original Series E offering documents. |
| Reporting Obligations | The Investor will receive quarterly financial statements and other information that is normally provided to public shareholders. |
| Termination | The agreement may be terminated early only under the conditions specified in the original Series E documentation or by mutual consent of the parties. |
Strategic Context
The stand‑still clause is intended to provide stability to the Company’s capital structure while allowing the Investor to maintain a long‑term stake. By preventing a sudden influx of shares into the market, the Company seeks to avoid dilution of existing shareholders and to preserve the value of its common equity.
20/20 Biolabs has been developing AI‑driven blood tests for early cancer detection (OneTest for Cancer) and for monitoring inflammatory biomarkers related to longevity (OneTest for Longevity). The firm’s clinical laboratory, the CLIAx Accelerator, supports overseas diagnostics startups, positioning the company at the intersection of precision medicine and global healthcare delivery.
Market Reaction
The announcement came after the Company’s most recent trading session on 21 July 2026, when the share price closed at $0.5491, a modest decline from the 52‑week low of $0.49 recorded on 19 July. The market’s reaction has been tempered by the Company’s negative price‑earnings ratio of -0.96, reflecting the early‑stage nature of its commercial operations and the ongoing investment required to expand its product pipeline.
Investors and analysts noted that the stand‑still agreement could improve confidence in the Company’s governance, potentially influencing future financing rounds or strategic partnerships. While the immediate financial impact on the share price appears limited, the agreement underscores 20/20 Biolabs’ commitment to maintaining a stable shareholder base as it navigates the competitive landscape of AI‑powered diagnostics.
Outlook
With the stand‑still in place, 20/20 Biolabs will continue to pursue regulatory approvals, scale its laboratory services, and expand market access for its diagnostic products. The Company’s future performance will hinge on successful commercialization of its early‑detection assays and the ability to capture a broader share of the growing precision‑medicine market.
